JP2023506227A - 免疫活性を強化するための組成物および方法 - Google Patents

免疫活性を強化するための組成物および方法 Download PDF

Info

Publication number
JP2023506227A
JP2023506227A JP2022535965A JP2022535965A JP2023506227A JP 2023506227 A JP2023506227 A JP 2023506227A JP 2022535965 A JP2022535965 A JP 2022535965A JP 2022535965 A JP2022535965 A JP 2022535965A JP 2023506227 A JP2023506227 A JP 2023506227A
Authority
JP
Japan
Prior art keywords
cells
ptpn2
acid
cell
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022535965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506227A5 (cg-RX-API-DMAC7.html
Inventor
イー リウ,
ジョナサン ディーン,
エイミー ストラスナー,
リアンシェン リー,
マシュー アール. ジェーンズ,
カレン ケー. ウォン,
ピンダ レン,
Original Assignee
カムクワット バイオサイエンシーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カムクワット バイオサイエンシーズ インコーポレイテッド filed Critical カムクワット バイオサイエンシーズ インコーポレイテッド
Publication of JP2023506227A publication Critical patent/JP2023506227A/ja
Publication of JP2023506227A5 publication Critical patent/JP2023506227A5/ja
Priority to JP2026031034A priority Critical patent/JP2026094293A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2022535965A 2019-12-12 2020-12-11 免疫活性を強化するための組成物および方法 Pending JP2023506227A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026031034A JP2026094293A (ja) 2019-12-12 2026-02-27 免疫活性を強化するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962947483P 2019-12-12 2019-12-12
US62/947,483 2019-12-12
PCT/US2020/064709 WO2021119554A1 (en) 2019-12-12 2020-12-11 Compositions and methods for potentiating immune activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026031034A Division JP2026094293A (ja) 2019-12-12 2026-02-27 免疫活性を強化するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2023506227A true JP2023506227A (ja) 2023-02-15
JP2023506227A5 JP2023506227A5 (cg-RX-API-DMAC7.html) 2023-12-18

Family

ID=76329104

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022535965A Pending JP2023506227A (ja) 2019-12-12 2020-12-11 免疫活性を強化するための組成物および方法
JP2026031034A Pending JP2026094293A (ja) 2019-12-12 2026-02-27 免疫活性を強化するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026031034A Pending JP2026094293A (ja) 2019-12-12 2026-02-27 免疫活性を強化するための組成物および方法

Country Status (7)

Country Link
US (1) US12551555B2 (cg-RX-API-DMAC7.html)
EP (1) EP4073242A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023506227A (cg-RX-API-DMAC7.html)
CN (1) CN115103907A (cg-RX-API-DMAC7.html)
AU (1) AU2020401376A1 (cg-RX-API-DMAC7.html)
CA (1) CA3163012A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021119554A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020401376A1 (en) 2019-12-12 2022-06-30 Kumquat Biosciences Inc. Compositions and methods for potentiating immune activity
CN114668743B (zh) * 2021-08-04 2025-08-08 贵州医科大学附属医院 抑制黑色素瘤生长的纳米载药系统的制备方法及应用
CN116251099B (zh) * 2023-04-30 2026-07-24 兰州大学第二医院 含苯氧基乙酰肼化合物的胰腺癌jak2和stat3双靶向抑制剂及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120088720A1 (en) * 2009-04-08 2012-04-12 Indiana University Research & Technology Corporati Inhibitors of protein tyrosine phosphatases
JP2017524348A (ja) * 2014-06-10 2017-08-31 モナッシュ ユニバーシティ 養子細胞移入のためのptpn2阻害を用いた白血球の産生方法
US20180325925A1 (en) * 2015-11-06 2018-11-15 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of neuroinflammatory disease, containing protein tyrosine phosphatase inhibitor
WO2018227248A1 (en) * 2017-06-13 2018-12-20 Monash University Methods and compositions for the treatment of obesity

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE534637T1 (de) 2002-04-03 2011-12-15 Novartis Ag 5-substituierte 1,1-dioxo- 1,2,5 thiazolidin-3- onderivate als ptpase 1b hemmer
GB0225986D0 (en) 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
UA94724C2 (en) 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
UA94921C2 (en) 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
RU2008127253A (ru) 2005-12-08 2010-01-20 Новартис АГ (CH) 1,1,3-триоксо-1,2,5-тиадиазолидины и их применение в качестве ингибиторов птфаз
JP2009532379A (ja) 2006-03-31 2009-09-10 ノバルティス アクチエンゲゼルシャフト PTPaseのチアジアゾリジノン阻害剤
AR066820A1 (es) 2007-06-04 2009-09-16 Novartis Ag Compuestos de tiadiazolidin-3 ona
WO2009049098A2 (en) 2007-10-09 2009-04-16 Indiana University Research & Technology Corporation Materials and methods for regulating the activity of phosphatases
CN103561573A (zh) 2011-04-26 2014-02-05 印第安纳大学研究与技术公司 酪氨酸磷酸酶及其在调节参与结核分枝杆菌之病理学的酶的活性中的用途
CA2977839C (en) * 2014-02-28 2022-07-26 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
IL308735A (en) * 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
US11311543B2 (en) 2016-05-27 2022-04-26 Yale University Compositions and methods for inhibiting PTPN22
WO2019036815A1 (en) 2017-08-24 2019-02-28 The Royal Institution For The Advancement Of Learning/Mcgill University ENHANCEMENT OF CD8 + T LYMPHOCYTES FOR ADOPTIVE CELL THERAPY BY INHIBITING PTPN1 (PTP1B) AND PTPN2 (TC-PTP))
WO2019178422A1 (en) * 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
TWI888352B (zh) 2018-06-21 2025-07-01 美商嘉來克生命科學有限責任公司 蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法
US20220081691A1 (en) * 2018-08-07 2022-03-17 Dana-Farber Cancer Institute, Inc Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
KR102983496B1 (ko) 2019-03-14 2026-06-29 칼리코 라이프 사이언시스 엘엘씨 단백질 티로신 포스파타제 억제제 및 이의 사용 방법
AU2020395612A1 (en) 2019-12-04 2022-06-09 Monash University Methods of activating cytotoxic leukocytes using PTP1B and PTPN2 inhibitors
AU2020401376A1 (en) 2019-12-12 2022-06-30 Kumquat Biosciences Inc. Compositions and methods for potentiating immune activity
MX2022007441A (es) 2019-12-18 2022-09-02 Calico Life Sciences Llc Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
CN116194453A (zh) 2019-12-20 2023-05-30 卡里科生命科学有限责任公司 蛋白质酪氨酸磷酸酶降解剂及其使用方法
CN113827727B (zh) 2020-06-24 2025-04-29 上海交通大学医学院附属瑞金医院 Ptpn2抑制剂在kras突变肿瘤中的应用
EP4211122A1 (en) 2020-09-11 2023-07-19 Calico Life Sciences LLC Protein tyrosine phosphatase inhibitors and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120088720A1 (en) * 2009-04-08 2012-04-12 Indiana University Research & Technology Corporati Inhibitors of protein tyrosine phosphatases
JP2017524348A (ja) * 2014-06-10 2017-08-31 モナッシュ ユニバーシティ 養子細胞移入のためのptpn2阻害を用いた白血球の産生方法
US20180325925A1 (en) * 2015-11-06 2018-11-15 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of neuroinflammatory disease, containing protein tyrosine phosphatase inhibitor
WO2018227248A1 (en) * 2017-06-13 2018-12-20 Monash University Methods and compositions for the treatment of obesity

Also Published As

Publication number Publication date
US20230044323A1 (en) 2023-02-09
EP4073242A1 (en) 2022-10-19
EP4073242A4 (en) 2024-01-03
US12551555B2 (en) 2026-02-17
CN115103907A (zh) 2022-09-23
AU2020401376A1 (en) 2022-06-30
CA3163012A1 (en) 2021-06-17
JP2026094293A (ja) 2026-06-09
WO2021119554A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
US20240398913A1 (en) Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
US20240076372A1 (en) Car t cell therapies with enhanced efficacy
US20240166641A1 (en) Heterocycles and uses thereof
WO2023096928A1 (en) Hetero-atom containing compounds and uses thereof
US20230074800A1 (en) Car-t cell therapies with enhanced efficacy
US12551555B2 (en) Compositions and methods for potentiating immune activity
TW201922774A (zh) 標靶bcma嵌合抗原受體、標靶cd19嵌合抗原受體及組合療法
BR112019019426A2 (pt) Biomarcadores e terapias com células t car com eficácia intensificada
US12503464B2 (en) 1,2,5-thiadiazolidin-3-one 1,1-dioxide containing compounds and uses thereof
JP2018512396A (ja) Th1応答を増強するためのrarアルファアゴニストを用いた併用療法
EP3227446A1 (en) Compositions and methods for diagnosis and treatment of prostate cancer
WO2021247534A2 (en) Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes
JP2018514517A (ja) レチノイン酸受容体−αアゴニストによる処置のための患者を層別化する方法
CA2918568A1 (en) Cytotoxic t cell response modifiers
US20250304570A1 (en) Benzo-fused n-heterocycles and uses thereof
WO2021119555A2 (en) Compositions and methods for potentiating immune response
CN118556056A (zh) 含杂原子的化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260317